Mark Goldberg
Director/Board Member bij AVACTA GROUP PLC
Vermogen: 2 M $ op 31-03-2024
Profiel
Mark Alan Goldberg is currently an Independent Director at GlycoMimetics, Inc., a Non-Executive Director at Avacta Group Plc, an Independent Director at Blueprint Medicines Corp., and a Director at Walden Biosciences, Inc. He previously served as an Independent Director at ImmunoGen, Inc., Idera Pharmaceuticals, Inc., and Astellas Gene Therapies, Inc. He was also a Director at aTyr Pharma, Inc., the American Cancer Society, Inc., and the American Cancer Society New England Division, Inc. Goldberg worked as a Senior Vice President-Clinical Research at Genzyme Corp.
and as an Executive VP-Global Medical & Regulatory Strategy at Synageva BioPharma Corp.
He was also the Chief Medical Officer at CANbridge Life Sciences Ltd.
Goldberg holds a doctorate from Harvard Medical School and an undergraduate degree from Harvard College.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-06-2023 | 16 012 ( 0.03% ) | 2 M $ | 31-03-2024 | |
GLYCOMIMETICS, INC.
0.06% | 29-03-2024 | 36 325 ( 0.06% ) | 108 975 $ | 31-03-2024 |
Actieve functies van Mark Goldberg
| Bedrijven | Functie | Begin |
|---|---|---|
| GLYCOMIMETICS, INC. | Director/Board Member | 10-07-2014 |
| BLUEPRINT MEDICINES CORPORATION | Director/Board Member | 25-06-2015 |
| AVACTA GROUP PLC | Director/Board Member | 18-08-2021 |
Walden Biosciences, Inc.
 Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Director/Board Member | - |
Eerdere bekende functies van Mark Goldberg
| Bedrijven | Functie | Einde |
|---|---|---|
| IMMUNOGEN, INC. | Director/Board Member | 12-02-2024 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Director/Board Member | 28-09-2022 |
| AUDENTES THERAPEUTICS, INC. | Director/Board Member | 15-01-2020 |
CANbridge Life Sciences Ltd.
 CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Chief Tech/Sci/R&D Officer | 23-07-2018 |
| Harvard Medical School | Corporate Officer/Principal | 01-01-2018 |
Opleiding van Mark Goldberg
| Harvard Medical School | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 5 |
|---|---|
| IMMUNOGEN, INC. | Health Technology |
| ATYR PHARMA, INC. | Health Technology |
| GLYCOMIMETICS, INC. | Health Technology |
| AVACTA GROUP PLC | Commercial Services |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Bedrijven in privébezit | 10 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
American Cancer Society, Inc.
 American Cancer Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Cancer Society, Inc. provides information on cancer occurrence, survival, prevention, early detection, and treatment. The non-profit company is based in Kennesaw, GA and has subsidiaries in the United States. The company's SHES department is an intramural research program with world-renowned epidemiologists and health scientists. The company was founded in 1913 by Candy Arrington. Karen E. Knudsen has been the CEO of the company since 2021. | Commercial Services |
| American Cancer Society New England Division, Inc. | |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Astellas Gene Therapies, Inc.
 Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
CANbridge Life Sciences Ltd.
CANbridge Life Sciences Ltd. Pharmaceuticals: MajorHealth Technology CANbridge Life Sciences Ltd. produces biopharmaceutical products. It engages in the research and development of therapeutic drug treatment for critical medical condition. The company was founded by James Xue on June 12, 2012 and is headquartered in Chaoyang, China. | Health Technology |
Walden Biosciences, Inc.
Walden Biosciences, Inc. Medical/Nursing ServicesHealth Services Walden Biosciences, Inc. provides renal therapeutics services. The company is headquartered in Cambridge, MA. | Health Services |
